Literature DB >> 30098475

NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure.

Adina Elena Stanciu1, Marcel Marian Stanciu2, Radu Gabriel Vatasescu3.   

Abstract

PURPOSE: Heart failure (HF) is considered to be a complex syndrome associated with neurohormonal and cytokine activation, that contribute to its progression. There are evidences which showed that, carbohydrate antigen 125 (CA 125), a tumor marker widely used for ovarian cancer therapy monitoring, was significantly elevated in HF patients. We hypothesized that inflammatory stimuli may be responsible for amino-terminal fragment of the prohormone B-type natriuretic peptide (NT-proBNP) and CA-125 production and release in chronic HF (CHF). We aimed to measure the levels of NT-proBNP, CA 125, pro-anti-inflammatory cytokines (IL-6, IL-1β, IL-8, TNF-α and IL-4), from peripheral venous (PV) and coronary sinus (CS) blood samples, in patients with CHF and to assess their correlation with echocardiographic indices.
METHODS: We enrolled 32 subjects (20M/12F) with CHF (III-IV NYHA functional class) who were to undergo cardiac resynchronization therapy (CRT) device implantation and 30 healthy controls (18M/12F). Two blood samples, from PV and CS, were collected at the time of CRT for each CHF patient. Serum levels of biomarkers were measured by ELISA. Cardiac function was assessed echocardiographically.
RESULTS: All investigated biomarkers were significantly higher in CHF patients than in non-CHF controls (P < 0.001). There were positive correlations between biomarkers concentrations in PV and CS (r between 0.54 and 0.98, all P < 0.003). NT-proBNP, IL-6 and IL-1β levels were 17%, 86% and 36% higher in CS than in PV, these increases being very well correlated each other, while CA 125 levels were 86% higher in PV than in CS. Moreover, CS NT-proBNP, CS IL-6 and CS IL-1β serum concentrations were inversely related to the echocardiographically determined left ventricular ejection fraction (LVEF) (r = -0.61, P < 0.001; r = -0.71, P < 0.001 and r = -0.48, P = 0.005, respectively). A positive relationship was found between CA 125 and IL-1β (r = 0.51, P = 0.003) in CS serum and between CA 125 and IL-6 (r = 0.43, P = 0.015), TNF-α (r = 0.46, P = 0.008) in PV serum. CA 125 concentrations were closely related to NT-proBNP both in CS (r = 0.46, P = 0.008) and PV (r = 0.52, P = 0.002).
CONCLUSIONS: CS sampling of NT-proBNP, CA 125 and pro-anti-inflammatory cytokines provides an additional insight into the possible mechanisms by which these biomarkers lead to left ventricular remodeling. Our results clearly suggest that serum NT-proBNP and CA 125 levels not only in PV, but also in CS of patients with CHF, may be dependent on inflammation as a consequence of cytokine network activation.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CA 125; Coronary sinus; Cytokines; Heart failure; Inflammation; NT-proBNP

Mesh:

Substances:

Year:  2018        PMID: 30098475     DOI: 10.1016/j.cyto.2018.07.037

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  Association between vascular comorbidity and glaucoma progression: A four-year observational study.

Authors:  Ana Maria Dascalu; Daniela Stana; Vanesa Andrada Nicolae; Catalin Cirstoveanu; Geta Vancea; Dragos Serban; Bogdan Socea
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

2.  Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation.

Authors:  Qingya Wang; Chengjing Dang; Haoyu Liu; Jie Hui
Journal:  BMC Cardiovasc Disord       Date:  2021-08-19       Impact factor: 2.298

3.  Optimization of a GF-AAS method for lead testing in blood and urine: A useful tool in acute abdominal pain management in emergency.

Authors:  Mihail Silviu Tudosie; Genica Caragea; Dragos Marian Popescu; Oana Avram; Dragos Serban; Catalin Gabriel Smarandache; Corneliu Tudor; Cristinel Dumitru Badiu; Bogdan Socea; Alexandru Dan Sabau; Meda Comandasu; Radu Spataru; Daniel Ovidiu Costea; Ciprian Tanasescu; Ana Maria Dascalu
Journal:  Exp Ther Med       Date:  2021-07-13       Impact factor: 2.447

Review 4.  Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values.

Authors:  Kuldeep Dhama; Shyma K Latheef; Maryam Dadar; Hari Abdul Samad; Ashok Munjal; Rekha Khandia; Kumaragurubaran Karthik; Ruchi Tiwari; Mohd Iqbal Yatoo; Prakash Bhatt; Sandip Chakraborty; Karam Pal Singh; Hafiz M N Iqbal; Wanpen Chaicumpa; Sunil Kumar Joshi
Journal:  Front Mol Biosci       Date:  2019-10-18

5.  The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation.

Authors:  Elton Amp Dudink; Bob Weijs; Samantha Tull; Justin Glm Luermans; Larissa Fabritz; Winnie Chua; Michiel Rienstra; Isabelle C Van Gelder; Ulrich Schotten; Paulus Kirchhof; Harry Jgm Crijns
Journal:  J Atr Fibrillation       Date:  2018-12-31

6.  CA-125 variation in acute heart failure: a single-centre analysis.

Authors:  Patrícia Lourenço; Filipe M Cunha; Catarina Elias; Catarina Fernandes; Isaac Barroso; João T Guimarães; Paulo Bettencourt
Journal:  ESC Heart Fail       Date:  2022-01-05

7.  CA125 as a Marker of Heart Failure in the Older Women: Population-Based Analysis.

Authors:  Weronika Bulska-Będkowska; Elżbieta Chełmecka; Aleksander J Owczarek; Katarzyna Mizia-Stec; Andrzej Witek; Aleksandra Szybalska; Tomasz Grodzicki; Magdalena Olszanecka-Glinianowicz; Jerzy Chudek
Journal:  J Clin Med       Date:  2019-05-03       Impact factor: 4.241

8.  Tumour biomarkers: association with heart failure outcomes.

Authors:  C Shi; H H van der Wal; H H W Silljé; M M Dokter; F van den Berg; L Huizinga; M Vriesema; J Post; S D Anker; J G Cleland; L L Ng; N J Samani; K Dickstein; F Zannad; C C Lang; P L van Haelst; J A Gietema; M Metra; P Ameri; M Canepa; D J van Veldhuisen; A A Voors; R A de Boer
Journal:  J Intern Med       Date:  2020-05-05       Impact factor: 8.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.